Whales with a lot of money to spend have taken a noticeably bearish stance on Vertex Pharmaceuticals.
Looking at options history for Vertex Pharmaceuticals VRTX we detected 8 trades.
If we consider the specifics of each trade, it is accurate to state that 25% of the investors opened trades with bullish expectations and 75% with bearish.
From the overall spotted trades, 2 are puts, for a total amount of $66,240 and 6, calls, for a total amount of $447,215.
Projected Price Targets
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $155.0 and $490.0 for Vertex Pharmaceuticals, spanning the last three months.
Volume & Open Interest Trends
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Vertex Pharmaceuticals's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Vertex Pharmaceuticals's whale activity within a strike price range from $155.0 to $490.0 in the last 30 days.
Vertex Pharmaceuticals 30-Day Option Volume & Interest Snapshot
Noteworthy Options Activity:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|
| VRTX | CALL | TRADE | NEUTRAL | 01/16/26 | $200.00 | $248.7K | 6 | 0 |
| VRTX | CALL | TRADE | NEUTRAL | 01/17/25 | $410.00 | $66.0K | 434 | 0 |
| VRTX | CALL | TRADE | BEARISH | 02/16/24 | $410.00 | $44.2K | 324 | 8 |
| VRTX | PUT | TRADE | BEARISH | 06/21/24 | $410.00 | $36.6K | 52 | 5 |
| VRTX | CALL | TRADE | BULLISH | 04/19/24 | $450.00 | $32.5K | 592 | 54 |
About Vertex Pharmaceuticals
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Having examined the options trading patterns of Vertex Pharmaceuticals, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
Vertex Pharmaceuticals's Current Market Status
- Currently trading with a volume of 502,888, the VRTX's price is down by -0.37%, now at $422.2.
- RSI readings suggest the stock is currently may be overbought.
- Anticipated earnings release is in 26 days.
What The Experts Say On Vertex Pharmaceuticals
Over the past month, 3 industry analysts have shared their insights on this stock, proposing an average target price of $391.3333333333333.
- An analyst from Cantor Fitzgerald has revised its rating downward to Overweight, adjusting the price target to $415.
- An analyst from Cantor Fitzgerald has revised its rating downward to Overweight, adjusting the price target to $380.
- An analyst from RBC Capital persists with their Sector Perform rating on Vertex Pharmaceuticals, maintaining a target price of $379.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Vertex Pharmaceuticals with Benzinga Pro for real-time alerts.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
